The American College of Phlebology 22nd Annual Congress: Marco Island, USA, 6–9 November 2008

摘要

Objective: Short- and mid-term side-effects of sclerotherapy, in particular with polidocanol, have been previously described in our registry of 12,173 sessions. With this follow-up registry, the incidence of long-term adverse events was evaluated. nnMethod: Physicians involved in the initial French registry have been contacted and asked to take part in the follow-up survey. Initially included patients have been controlled at the latest possible date in order to determine whether a complication had occurred after the end of the initial survey. nnResults: Data on 1605 patients included during the initial registry have been reviewed with a maximum follow-up of 60 months covering 3357 patient years. A total of five adverse events have been observed in patients treated with liquid polidocanol and 46 adverse events in patients treated with foam. Most frequent side-effects were visual disturbances with a total number of 14 and most severe were eight muscular vein thrombosis. The onset of side-effects was mostly observed directly after sclerotherapy or in the first six months afterwards (87% in the first year). One deep vein thrombosis recurrence occurred in a patient with heterozygote Factor V Leiden after stopping anticoagulant treatment. nnConclusion: Sclerotherapy with polidocanol is safe, especially long term. The use of liquid, with an incidence of side-effects lower than 0.4%, is perfectly fit for the treatment of benign lesions, such as small varices, reticular veins or telangiectasias, whereas foamed polidocanol used in the treatment of large varicose veins presents less side-effects than surgery with which it now competes. nnPotential conflict of interest? Yes. Conflict details: honoraria main investigator of the study. nnOutside funding? Yes. Funding details: Kreussler Pharma, Wiesbaden, Germany.